drug launches

Novo Nordisk raised its 2026 outlook following strong sales performance from its newly launched Wegovy pill, which exceeded forecasts. This demonstrates the pharmaceutical sector's ability to drive significant stock gains through successful product launches in high-demand therapeutic areas like obesity treatment.